Bacterial β-(1,3)-glucan prevents DSS-induced IBD by restoring the reduced population of regulatory T cells

Immunobiology

Volumn 219, Issue 10, 2014, Pages 802-812

  Lee, Kwang Ho ^a   Park, Min ^a   Ji, Kon Young ^a   Lee, Hwa Youn ^a   Jang, Ji Hun ^a   Yoon, Il Joo ^a   Oh, Seung Su ^a   Kim, Su Man ^a   Jeong, Yun Hwa ^a   Yun, Chul Ho ^a   Kim, Mi Kyoung ^b   Lee, In Young ^b   Choi, Ha Rim ^c   Ko, Ki sung ^d   Kang, Hyung Sik ^a  

^a Chonnam National University   (South Korea)

^b Naturence Co Ltd Tanchun Industrial Complex   (South Korea)

^c Nambu University   (South Korea)

^d Chung Ang University   (South Korea)

Author keywords

Bacterial (1,3) glucan; Dextran sulfate sodium (DSS); Immunoglobulin A; Inflammatory bowel disease; Natural killer cell; Regulatory T cell

Indexed keywords

BETA 1,3 GLUCAN; CYTOKINE; DEXTRAN SULFATE; IMMUNOGLOBULIN A; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 1BETA; INTERLEUKIN 6; ANTIINFLAMMATORY AGENT; BETA GLUCAN; BETA-1,3-D-GLUCAN; REACTIVE OXYGEN METABOLITE;

AGROBACTERIUM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; IN VIVO STUDY; INFLAMMATORY BOWEL DISEASE; LYMPHOCYTE COUNT; MACROPHAGE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CHEMISTRY; COLON; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; FECES; FIBROBLAST; GENETICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; LYMPH NODE; METABOLISM; PATHOLOGY;

AGROBACTERIUM; ANIMALS; ANTI-INFLAMMATORY AGENTS; BETA-GLUCANS; CELL PROLIFERATION; COLON; CYTOKINES; DEXTRAN SULFATE; EPITHELIAL CELLS; FECES; FIBROBLASTS; GENE EXPRESSION; IMMUNOGLOBULIN A; INFLAMMATORY BOWEL DISEASES; KILLER CELLS, NATURAL; LYMPH NODES; MALE; MICE, INBRED C57BL; REACTIVE OXYGEN SPECIES; T-LYMPHOCYTES, REGULATORY;

EID: 84906791900     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2014.07.003     Document Type: Article

References (56)

1. Akramiene D., Kondrotas A., Didziapetriene J., Kevelaitis E. Effects of beta-glucans on the immune system. Medicina (Kaunas) 2007, 43:597-606.
2. Allez M., Mayer L. Regulatory T cells: peace keepers in the gut. Inflamm. Bowel Dis. 2004, 10:666-676.
3. Asseman C., Mauze S., Leach M.W., Coffman R.L., Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 1999, 190:995-1004.
4. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-1657.
5. Boden E.K., Snapper S.B. Regulatory T cells in inflammatory bowel disease. Curr. Opin. Gastroenterol. 2008, 24:733-741.
6. Brown G.D., Gordon S. Immune recognition of fungal β-glucans. Cell Microbiol. 2005, 7:471-479.
7. Chen J., Seviour R. Medicinal importance of fungal beta-(1→3), (1→6)-glucans. Mycol. Res. 2007, 111:635-652.
8. Coombes J.L., Robinson N.J., Maloy K.J., Uhlig H.H., Powrie F. Regulatory T cells and intestinal homeostasis. Immunol. Rev. 2005, 204:184-194.
9. Davis I.A., Knight K.A., Rouse B.T. The spleen and organized lymph nodes are not essential for the development of gut-induced mucosal immune responses in lymphotoxin-alpha deficient mice. Clin. Immunol. Immunopathol. 1998, 89:150-159.
10. Debnath T., Kim da H., Lim B.O. Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease. Molecules 2013, 18:7253-7270.
11. Deguchi Y., Andoh A., Inatomi O., Yagi Y., Bamba S., Araki Y., Hata K., Tsujikawa T., Fujiyama Y. Curcumin prevents the development of dextran sulfate sodium (DSS)-induced experimental colitis. Dig. Dis. Sci. 2007, 52:2993-2998.
12. Dupaul-Chicoine J., Yeretssian G., Doiron K., Bergstrom K.S., McIntire C.R., LeBlanc P.M., Meunier C., Turbide C., Gros P., Beauchemin N., Vallance B.A., Saleh M. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 2010, 32:367-378.
13. Fan H.Y., Zhang Z.L., Liu K., Yang M.Y., Lv W.H., Che X., Xu H., Song W.W. Effectiveness of a hydroxynaphthoquinone fraction from Arnebia euchroma in rats with experimental colitis. World J. Gastroenterol. 2013, 19:9318-9327.
14. + regulatory T cells reveals innate-like features: implications for immune-regulatory repertoire. Hum. Immunol. 2012, 73:214-222.
15. Farooq S.M., Stillie R., Svensson M., Svanborg C., Strieter R.M., Stadnyk A.W. Therapeutic effect of blocking CXCR2 on neutrophil recruitment and dextran sodium sulfate-induced colitis. J. Pharmacol. Exp. Ther. 2009, 329:123-129.
16. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998, 115:182-205.
17. + regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J. Exp. Med. 2005, 202:1075-1085.
18. Groux H., Powrie F. Regulatory T cells and inflammatory bowel disease. Immunol. Today 1999, 20:442-445.
19. Guerra Dore C.M., Azevedo T.C., de Souza M.C., Rego L.A., de Dantas J.C., Silva F.R., Rocha H.A., Baseia I.G., Leite E.L. Antiinflammatory, antioxidant and cytotoxic actions of β-glucan-rich extract from Geastrum saccatum mushroom. Int. Immunopharmacol. 2007, 7:1160-1169.
20. Haddad P.S., Azar G.A., Groom S., Boivin M. Natural health products, modulation of immune function and prevention of chronic diseases. Evid. Based Complement Altern. Med. 2005, 2:513-520.
21. Hendrickson B.A., Gokhale R., Cho J.H. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev. 2002, 15:79-94.
22. Huibregtse I.L., van Lent A.U., van Deventer S.J. Immunopathogenesis of IBD: insufficient suppressor function in the gut?. Gut 2007, 56:584-592.
23. Hur S.J., Kang S.H., Jung H.S., Kim S.C., Jeon H.S., Kim I.H., Lee J.D. Review of natural products actions on cytokines in inflammatory bowel disease. Nutr. Res. 2012, 32:801-816.
24. Ishikawa D., Okazawa A., Corridoni D., Jia L.G., Wang X.M., Guanzon M., Xin W., Arseneau K.O., Pizarro T.T., Cominelli F. Tregs are dysfunctional in vivo in a spontaneous murine model of Crohn's disease. Mucosal Immunol. 2013, 6:267-275.
25. Ito R., Shin-Ya M., Kishida T., Urano A., Takada R., Sakagami J., Imanishi J., Kita M., Ueda Y., Iwakura Y., Kataoka K., Okanoue T., Mazda O. Interferon gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin. Exp. Immunol. 2006, 146:330-338.
26. Itzkowitz S.H., Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:G7-G17.
27. Jeffers M., McDonald W.F., Chillakuru R.A., Yang M., Nakase H., Deegler L.L., Sylander E.D., Rittman B., Bendele A., Sartor R.B., Lichenstein H.S. A novel human fibroblast growth factor treats experimental intestinal inflammation. Gastroenterology 2002, 123:1151-1162.
28. Jobin C., Sartor R.B. The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection. Am. J. Physiol. Cell Physiol. 2000, 278:C451-C462.
29. Jurjus A.R., Khoury N.N., Reimund J.M. Animal models of inflammatory bowel disease. J. Pharmacol. Toxicol. Methods 2004, 50:81-92.
30. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu. Rev. Immunol. 2010, 28:573-621.
31. Kim M.K., Ryu K.E., Choi W.A., Rhee Y.H., Lee I.Y. Enhanced production of (1→3)-β-d-glucan by a mutant strain of Agrobacterium species. Biochem. Eng. J. 2003, 16:163-168.
32. Kim S.Y., Song H.J., Lee Y.Y., Cho K.H., Roh Y.K. Biomedical issues of dietary fiber β-glucan. J. Korean Med. Sci. 2006, 21:781-789.
33. Lavi I., Levinson D., Peri I., Nimri L., Hadar Y., Schwartz B. Orally administered glucans from the edible mushroom Pleurotus pulmonarius reduce acute inflammation in dextran sulfate sodium-induced experimental colitis. Br. J. Nutr. 2010, 103:393-402.
34. Lessard M., Dupuis M., Gagnon N., Nadeau E., Matte J.J., Goulet J., Fairbrother J.M. Administration of Pediococcus acidilactici or Saccharomyces cerevisiae boulardii modulates development of porcine mucosal immunity and reduces intestinal bacterial translocation after Escherichia coli challenge. J. Anim. Sci. 2009, 87:922-934.
35. + regulatory T cells. J. Immunol. 2005, 175:4180-4183.
36. Liu Z., Feng B.S., Yang S.B., Chen X., Su J., Yang P.C. Interleukin (IL)-23 suppresses IL-10 in inflammatory bowel disease. J. Biol. Chem. 2012, 287:3591-3597.
37. Mantovani M.S., Bellini M.F., Angeli J.P., Olivera R.J., Silva A.F., Ribeiro L.R. β-glucans in promoting health: prevention against mutation and cancer. Mutat. Res. 2008, 658:154-161.
38. Manzano L., Alvarez-Mon M., Abreu L., Antonio Vargas J., de la Morena E., Corugedo F., Dur'antez A. Functional impairment of natural killer cells in active ulcerative colitis: reversion of the defective natural killer activity by interleukin 2. Gut 1992, 33:246-251.
39. McNamee E.N., Masterson J.C., Jedlicka P., McManus M., Grenz A., Collins C.B., Nold M.F., Nold-Petry C., Bufler P., Dinarello C.A., Rivera-Nieves J. Interleukin 37 expression protects mice from colitis. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16711-16716.
40. Namba T., Tanaka K., Ito Y., Ishihara T., Hoshino T., Gotoh T., Endo M., Sato K., Mizushima T. Positive role of CCAAT/enhancer-binding protein homologous protein, a transcription factor involved in the endoplasmic reticulum stress response in the development of colitis. Am. J. Pathol. 2009, 174:1786-1798.
41. Neurath M.F., Fuss I., Schürmann G., Pettersson S., Arnold K., Müller-Lobeck H., Strober W., Herfarth C., Büschenfelde K.H. Cytokine gene transcription by NF-(B family members in patients with inflammatory bowel disease. Ann. N. Y. Acad. Sci. 1998, 859:149-159.
42. Pandolfi F., Cianci R., Pagliari D., Landolfi R., Cammarota G. Cellular mediators of inflammation: tregs and TH17 cells in gastrointestinal diseases. Mediat. Inflamm. 2009, 2009:1-11.
43. Podolsky D.K. Inflammatory bowel disease. N. Engl. J. Med. 2002, 347:417-429.
44. Sandborn W.J. Serologic markers in inflammatory bowel disease: state of the art. Rev. Gastroenterol. Disord. 2004, 4:167-174.
45. Singh B., Read S., Asseman C., Malmström V., Mottet C., Stephens L.A., Stepankova R., Tlaskalova H., Powrie F. Control of intestinal inflammation by regulatory T cells. Immunol. Rev. 2001, 182:190-200.
46. + Treg-mediated suppression. Trends Immunol. 2008, 29:337-342.
47. Spicer E.J., Goldenthal E.I., Ikeda T. A toxicological assessment of curdlan. Food Chem. Toxicol. 1999, 37:455-479.
48. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 2002, 20:495-549.
49. + self-reactive T cells. J. Immunol. 2008, 180:4679-4686.
50. Waite J.C., Skokos D. Th17 response and inflammatory autoimmune diseases. Int. J. Inflamm. 2012, 2012:1-10.
51. Wang F., Zhao H.Y., Zhang S.T., Gong Y.Z., Zhang H.F., Zhang C. Effect of enteral nutrition on dextran sulfate sodium-induced colitis in rats. J. Dig. Dis. 2011, 12:453-458.
52. Wirtz S., Neurath M.F. Mouse models of inflammatory bowel disease. Adv. Drug. Deliv. Rev. 2007, 59:1073-1083.
53. Wu L.H., Xu Z.L., Dong D., He S.A., Yu H. Protective effect of anthocyanins extract from blueberry on TNBS-induced IBD model of mice. Evid. Based Complement Altern. Med. 2011, 2011:1-8.
54. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
55. Yadav P.K., Chen C., Liu Z. Potential role of NK cells in the pathogenesis of inflammatory bowel disease. J. Biomed. Biotechnol. 2011, 2011:1-6.
56. Zeković D.B., Kwiatkowski S., Vrvić M.M., Jakovljević D., Moran C.A. Natural and modified (1→3)-beta-d-glucans in health promotion and disease alleviation. Crit. Rev. Biotechnol. 2005, 25:205-230.